<DOC>
	<DOCNO>NCT02937974</DOCNO>
	<brief_summary>Objective : A prospective multicenter randomize control trial ass efficacy safety Xuebijing injection acute exacerbation chronic obstructive pulmonary disease ( AECOPD ) . Methods : 254 AECOPD inpatient recruit 6 hospital China 2 year . They randomly assign Experimental group Placebo group，Experimental : Xuebijing injection 50ml 100ml Normal Saline IV , 80mins , per 12 hour . administration agent consecutive 5 days；Placebo Comparator : Normal Saline 150ml IV , 80mins , per 12 hour . administration agent consecutive 5 day . Compare follow index two group : Invasive mechanical ventilation rate , length hospital stay , Treg cell , Th1 , Th2 , HLA-DR , CRP , PCT , IL-4 , IL-6 , IL-10 , TNF-α，IFN-γ , APACHEⅡ , CAPS score .</brief_summary>
	<brief_title>Evaluate Efficacy Xuebijing Injection Acute Exacerbations COPD</brief_title>
	<detailed_description>A prospective multicenter randomize control trial ass efficacy safety Xuebijing injection acute exacerbation chronic obstructive pulmonary disease ( AECOPD ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Body weight≥40kg ≤100kg 2 . Diagnosis COPD : ( follow Global initiative Chronic Obstructive Lung Disease，GOLD2016 ) 3 . Forced Expiratory Volume 1 second less 70 % predict value bronchodilator 4 . Acute exacerbation COPD : clinical presentation patient complain acute change symptom ( baseline dyspnea , cough , and/or sputum production ) beyond normal daytoday variation . 5 . Assessment COPD Exacerbations : Medical History : severity COPD base degree airflow limitation ; Duration worsen new symptom ; Number previous episode ( total/hospitalizations ) ; Comorbidities ; Present treatment regimen ; Previous use mechanical ventilation ; 6. sign inform consent 1 . Pregnant woman , lactate women； 2 . Be allergic Xuebijing； 3 . Acute exacerbation COPD onset 72 hours； 4 . AECOPD severe hypoxemia：oxygenation index &lt; 150 received Endotracheal intubation invasive mechanical ventilation； 5 . Participation another experimental protocol within 30 day study entry 6 . Primary diseases：Asthma，Cystic fibrosis，Lung cancer，Tuberculosis，Pulmonary sarcoidosis，Pulmonary interstitial fibrosis，Malignant neoplasms，Blood system diseases，HIV； 7 . Complications：Pulmonary embolism，shock，DIC，Unstable cardiovascular disease，Upper gastrointestinal bleeding，pneumothorax，Severe liver kidney dysfunction； 8 . Mental incompetence active psychiatric illness 9. use follow drug within 72 hour day study entry：Ulinastatin，Tanreqing， Reduning，Qingkailing； 10 . The investigator judge subject could complete participate trial：Hemodialysis 1 mouth，Organ transplant patient potential medical dispute .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>Xuebijing</keyword>
</DOC>